論文

2022年

Risk Assessment of Neutropenia during Low-Dose Valganciclovir Prophylaxis for Heart Transplant Recipients.

Biological & pharmaceutical bulletin
  • Mai Otokubo
  • Kyoichi Wada
  • Megumi Ikura
  • Kotoka Hayase
  • Takaya Uno
  • Kazuki Nakagita
  • Naoki Hayakawa
  • Takuya Watanabe
  • Osamu Seguchi
  • Norihide Fukushima
  • Tsutomu Nakamura
  • 全て表示

45
4
開始ページ
452
終了ページ
459
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1248/bpb.b21-00860

The aim of this study was to investigate whether low-dose valganciclovir (VGCV) prophylaxis for cytomegalovirus (CMV) infection increased the risk of developing neutropenia in heart transplant recipients (HTRs). Forty-three HTRs receiving VGCV were divided into two groups: those who received VGCV prophylaxis (n = 22) and those who did not (n = 21). Neutropenia was defined as an absolute neutrophil count ˂1500/µL and was monitored for approximately one year post-transplantation. In the prophylaxis group, 77.3% (17/22) of HTRs experienced neutropenia, which was significantly higher than that in the no prophylaxis group (42.9% [9/21], p = 0.031). No significant differences in the duration of VGCV administration and cumulative dose up to the first neutropenia episode were observed between the groups. Meanwhile, the cumulative dose of mycophenolate mofetil was significantly higher in the prophylaxis group than in the no prophylaxis group (p = 0.018); the daily maintenance dose and regularly measured area under the concentration-time curve (AUC) of mycophenolic acid did not significantly differ between groups. In conclusion, the risk of developing neutropenia was higher in HTRs receiving low-dose VGCV prophylaxis than it was in those not receiving prophylaxis, probably not attributed to dosing period and cumulative dose of VGCV until the onset of neutropenia.

リンク情報
DOI
https://doi.org/10.1248/bpb.b21-00860
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35370269
ID情報
  • DOI : 10.1248/bpb.b21-00860
  • PubMed ID : 35370269

エクスポート
BibTeX RIS